Oruka Therapeutics Quarterly Cash Flow Statement
NASDAQ: ORKAHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
82.11+4.83 (+6.25%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Oruka Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Oruka Therapeutics generated -$33.1 million of operating cash flow and spent $0 on capital expenditures. That left free cash flow of -$33.1 million.
Summary generated from market data by MetaCap's automated system. Methodology
Oruka Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 | Q1 20232023-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -41.21M | -31.82M | -29.58M | -30.28M | -24.57M | -21.00M | -28.62M | -22.24M | -2.01M | -1.09M | -1.42M | -1.48M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 43.00K | 43.00K | 28.00K | 20.00K | 19.00K | 16.00K | — | 3.00K | 3.00K | 3.00K | 4.00K | 4.00K |
| Stock-Based Compensation | 7.28M | 6.97M | 4.12M | 10.16M | 5.08M | 4.88M | 9.00M | 112.00K | 114.00K | 141.00K | 154.00K | 187.00K |
| Change in Working Capital | -4.64M | 461.00K | -805.00K | -2.40M | -617.00K | -148.00K | -259.00K | 42.00K | 167.00K | 40.00K | 81.00K | -125.00K |
| Operating Cash Flow | -33.15M | -23.58M | -22.59M | -21.60M | -23.14M | -20.87M | -27.82M | -2.63M | -1.53M | -1.06M | -1.67M | -694.00K |
| Capital Expenditures | 0 | -73.00K | -63.00K | -99.00K | -34.00K | -13.00K | — | — | — | — | — | — |
| Investing Cash Flow | -410.95M | -14.44M | -22.02M | -122.45M | 4.86M | 42.87M | — | 0 | 0 | — | — | 0 |
| Financing Cash Flow | 663.04M | 40.60M | 298.00K | 169.91M | — | — | 423.74M | 14.00K | 0 | — | — | 0 |
| Net Change in Cash | 218.95M | 2.58M | -44.32M | 25.86M | -18.18M | 22.00M | 395.75M | -2.62M | -1.53M | -1.06M | -1.67M | -694.00K |
| Free Cash Flow | -33.15M | -23.65M | -22.66M | -21.70M | -23.18M | -20.88M | -27.82M | -2.63M | -1.53M | -1.06M | -1.67M | -694.00K |
This table shows 12 quarterly periods of Oruka Therapeutics's cash flow statement, from Q2 2026 back to Q1 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ORKA's reporting calendar. What is a cash flow statement?